Recordati “very pleased” with 2009 sales so far

Recordati has announced its satisfaction with the number of sales it has achieved so far this year.

The company made its comments as it published its financial results for the first half of 2009, which saw its group revenues reach a total of 379.3 million euros (326.1 million pounds), an 8.9 per cent rise on the same period last year.

Meanwhile, pharmaceutical sales increased by 10.1 per cent.

Revenue growth was attributed to the company’s international business, which saw increases of 12.5 per cent over the six-month period.

Commenting, Giovanni Recordati, chairman and chief executive of the company, said the results demonstrate the validity of the firm’s plans to expand its pharmaceutical operations, predominantly through the enhancement of its product portfolio.

“We are very pleased with the sales achieved in the first half of the year,” he added.

Earlier this month, the company announced an agreement with Amdipharm, which will allow it to market and sell the transdermal patch TransAct LAT in certain markets.